Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms
pharmaceutical-investing Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing
pharmaceutical-investing 1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
pharmaceutical-investing Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
